Chemotherapy-induced nausea and vomiting in clinical practice: Impact on patients' quality of life

Supportive Care in Cancer

Volumn 20, Issue 12, 2012, Pages 3141-3148

  Fernandez Ortega P ^a   Caloto, M T ^b   Chirveches, E ^c   Marquilles, R ^d   San Francisco, J ^e   Quesada, A ^f   Suarez C ^g   Zorrilla, I ^h   Gomez J ⁱ   Zabaleta, P ^j   Nocea, G ^b   Llombart Cussac, A ^k,l  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b MSD   (Spain)

^c HOSPITAL GENERAL DE VIC   (Spain)

^d HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f HOSPITAL JOSEP TRUETA   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j Instituto Oncológico Guipúzcoa   (Spain)

^k UNIVERSITY OF LLEIDA   (Spain)

^l HOSPITAL ARNAU DE VILANOVA   (Spain)

more..

Author keywords

Chemotherapy induced nausea and vomiting; Emetogenous chemotherapy; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; SEROTONIN 3 ANTAGONIST; VINBLASTINE;

ADULT; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLON CANCER; FEMALE; FUNCTIONAL LIVING INDEX EMESIS QUESTIONNAIRE; GYNECOLOGIC CANCER; HUMAN; LUNG CANCER; LYMPHATIC SYSTEM TUMOR; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RECTUM CANCER; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; VOMITING;

EID: 84868481728     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1448-1     Document Type: Article

References (41)

1. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219-227
2. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116-23
3. Booth CM, Clemons M, Dranitsaris G et al (2007) Chemotherapyinduced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 5:374-80
4. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS (2002) Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 10:139-45
5. The Pallium Project (2006) Learning Essential Approaches to Palliative and End-of-Life Care (LEAP) facilitator manual version 1.1 [module 2, slide 5; gastrointestinal problems in palliative care]. Edmonton: The Pallium Project..
6. Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present and future recommendations. Oncologist 12:1143-1150
7. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482-94
8. Ruhlmann CH, Herrstedt J (2012) Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 12:139-50
9. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
10. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference (1998) Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 9:811-819
11. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947
12. Roila F, Hesketh PJ, Herrstedt J et al (2006) Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the (2004) Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis, V.1.2007. Available at http://www.nccn.org/ professionals/physician-gls/PDF/antiemesis.pdf. Accessed August 3, 2007..
14. Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497-503
15. Bloechl-Daum B, Deuson RR, Mavros P et al (2006) (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-8
16. Gralla RJ (2005) deWit R, Herrstedt J, et al. (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5-HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104:864-8
17. Voliotis DL, Diehl V (1998) Clinical aspects and prognostic factors of nausea and vomiting after chemotherapy. In: DiCato MA (ed) Medical management of cancer treatment induced emesis. Martin Dunitz, Philadelphia, pp 45-54
18. Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R (2005) Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2(3):181-7
19. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-8
20. Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G et al (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179-85
21. Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and vomiting after modern emetics. Cancer 10:2261-2668
22. Borjeson S, Hursti TJ, Peterson C et al (1997) Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs 20:260-266
23. Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the functional living indexcancer: development and validation. J Clin Oncol 2:472-483
24. Martin AR, Pearson J, Cai B, Elmer M, Horgan K, Lindley C (2000) Validation of a 5-day recall version of the functional living index-emesis (FLIE) quality of life questionnaire for chemotherapyinduced emesis. Qual Life Res 9:18-24
25. Gridelli C, Haiderali AM, Russo MW, Blackburn LM, Lykopoulos K (2011) Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. Support Care Cancer 18:1437-44
26. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880-6
27. Glaus A, Knipping C, Morant R et al (2004) Chemotherapy induced nausea and vomiting in routine practice - a European perspective. Support Care Cancer 12:708-15
28. Ballatori E, Roila F, Ruggeri B et al (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179-85
29. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497-503
30. Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R (2005) Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2:181-7
31. Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-9
32. Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic contol. Oncologist 8:187-98
33. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35-41
34. Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea an emesis after modern antiemetics. Cancer 100:2261-2268
35. Majem M, Moreno ME, Calvo N, et al. (2011) Perception of health care providers versus patient reported incidence of chemotherapyinduced nausea and vomiting after the addition of NK-1 receptor antagonists 19:1983-90..
36. Roila F, Hesketh PJ, Herrstedt J et al (2006) Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
37. Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2:80-84
38. Morrow GR, Hickok JT, Burish TG et al (1996) Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol 19:199-203
39. Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20:113-21
40. Gómez-Raposo C, Feliú-Batle J, González-Barón M (2006) Prevención y control de las náuseas y los vómitos inducidos por quimioterapia. Med Clin (Barc) 126:143-51
41. Ettinger DS, Armstrong DK, Barbour S et al (2009) Antiemesis. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7:572-95